Aristopharma Ltd. proudly announces the launch of Lexivo, a new Escitalopram brand developed for the treatment of MDD,OCD, PTSD & SAD.

Lexivo (Escitalopram) is a well-established therapy that increases serotonin availability in the brain, helping improve mood, emotional stability, and anxiety-related symptoms.

Available in 5 mg and 10 mg tablets, Lexivo supports flexible dose optimization and long-term management of depressive and anxiety disorders. Its proven effectiveness, good safety profile, and ease of use make Lexivo a rational choice for patients requiring antidepressant therapy.